← Leaderboards
Thomas P Loughran
University Of Virginia
$27,014,958
Attributed
$32,058,443
Total exposure
29
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.9M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$88,315,237 · 32
By mechanism
P30$44,798,780 · 11
P01$27,592,841 · 8
R01$13,020,508 · 5
T32$1,349,140 · 1
K12$749,445 · 1
K24$631,905 · 1
Top collaborators
- Mark Kester17 shared
- Donald E Brown5 shared
- Ross C Hardison5 shared
- Jason Papin5 shared
- Kevin Skadron5 shared
- Hong-Gang Wang5 shared
- Mary L. Poss3 shared
- Myles C Cabot2 shared
Most similar at University Of Virginia
Same institution · by research overlap
- Craig Lee Slingluff$18,119,839
- Jeffrey Chunlong Xing$185,468
- Aakrosh Ratan$734,604
- Kimberly A. Kelly$7,276,942
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsProgramsFundingCancer CenterUniversity Of Virginia Cancer CenterCancer Center Support GrantBasic ScienceClinical ResearchMemberResource SharingCollaborationsFaculty RecruitmentResourcesLeadershipTranslational ResearchClinical TrialsAreaResearch PersonnelSignal TransductionVirginiaScienceFutureScientistMission
Grant awards (172)
Ceramide-Directed Therapeutics for Treatment of AML$2,663,053
P01 · FY2025 · CA · contact PI
University of Virginia Cancer Center Support Grant$2,602,707
P30 · FY2025 · CA · contact PI
Genomic Architecture of LGL Leukemia$680,771
R01 · FY2025 · CA · contact PI
Development Funds$500,030
P30 · FY2025 · CA · contact PI
Project 2$416,073
P01 · FY2025 · CA · contact PI
Leadership, Planning & Evaluation$410,310
P30 · FY2025 · CA · contact PI
Administrative Core$214,692
P01 · FY2025 · CA · contact PI
University of Virginia Cancer Center Support Grant$201,875
P30 · FY2025 · CA · contact PI
University of Virginia Cancer Center Support Grant$2,602,707
P30 · FY2024 · CA · contact PI
Targeted Sphingolipid Metabolism for Treatment of AML$1,894,532
P01 · FY2024 · CA · contact PI
Genomic Architecture of LGL Leukemia$680,771
R01 · FY2024 · CA · contact PI
Development Funds$500,031
P30 · FY2024 · CA · contact PI
Leadership, Planning & Evaluation$410,312
P30 · FY2024 · CA · contact PI
Targeting Acid Ceramidase in AML$318,309
P01 · FY2024 · CA · contact PI
Adipokine Signaling in Melanoma: Unmasking the Obesity Paradox.$201,875
P30 · FY2024 · CA · contact PI
Administrative Core$132,734
P01 · FY2024 · CA · contact PI
University of Virginia Cancer Center Support Grant$2,602,707
P30 · FY2023 · CA · contact PI
Targeted Sphingolipid Metabolism for Treatment of AML$1,954,358
P01 · FY2023 · CA · contact PI
Development Funds$500,030
P30 · FY2023 · CA · contact PI
Leadership, Planning & Evaluation$410,312
P30 · FY2023 · CA · contact PI
Targeting Acid Ceramidase in AML$328,361
P01 · FY2023 · CA · contact PI
Administrative Core$136,925
P01 · FY2023 · CA · contact PI
University of Virginia Cancer Center Support Grant$2,602,707
P30 · FY2022 · CA · contact PI
Targeted Sphingolipid Metabolism for Treatment of AML$1,954,358
P01 · FY2022 · CA · contact PI
Development Funds$500,030
P30 · FY2022 · CA · contact PI
Leadership, Planning & Evaluation$410,312
P30 · FY2022 · CA · contact PI
Targeting Acid Ceramidase in AML$328,361
P01 · FY2022 · CA · contact PI
Administrative Core$136,925
P01 · FY2022 · CA · contact PI
University of Virginia Cancer Center Support Grant$2,602,707
P30 · FY2021 · CA · contact PI
Targeted Sphingolipid Metabolism for Treatment of AML$1,995,479
P01 · FY2021 · CA · contact PI
Cancer Center Administration$661,552
P30 · FY2021 · CA · contact PI
Developmental Funds$653,035
P30 · FY2021 · CA · contact PI
Targeting Acid Ceramidase in AML$335,061
P01 · FY2021 · CA · contact PI
Administrative Core$139,718
P01 · FY2021 · CA · contact PI
Flow Cytometry Core$83,511
P30 · FY2021 · CA · contact PI
Advanced Microscopy Facility$62,961
P30 · FY2021 · CA · contact PI
Planning and Evaluation$50,472
P30 · FY2021 · CA · contact PI
University of Virginia Cancer Center Support Grant$2,602,707
P30 · FY2020 · CA · contact PI
Targeted Sphingolipid Metabolism for Treatment of AML$2,054,089
P01 · FY2020 · CA · contact PI
Cancer Center Administration$661,552
P30 · FY2020 · CA · contact PI
Developmental Funds$653,035
P30 · FY2020 · CA · contact PI
Genomic Architecture of LGL Leukemia$608,386
R01 · FY2020 · CA · contact PI
Targeting Acid Ceramidase in AML$316,211
P01 · FY2020 · CA · contact PI
Transdisciplinary Big Data Science Training at UVa$297,628
T32 · FY2020 · LM
University of Virginia Cancer Center Support Grant$149,983
P30 · FY2020 · CA · contact PI
Administrative Core$143,653
P01 · FY2020 · CA · contact PI
University of Virginia Cancer Center Support Grant$124,862
P30 · FY2020 · CA · contact PI
University of Virginia Cancer Center Support Grant$100,001
P30 · FY2020 · CA · contact PI
Flow Cytometry Core$83,511
P30 · FY2020 · CA · contact PI
Advanced Microscopy Facility$62,961
P30 · FY2020 · CA · contact PI
Planning and Evaluation$50,472
P30 · FY2020 · CA · contact PI
University of Virginia Cancer Center Support Grant$25,000
P30 · FY2020 · CA · contact PI
University of Virginia Cancer Center Support Grant$2,602,707
P30 · FY2019 · CA · contact PI
Cancer Center Administration$653,049
P30 · FY2019 · CA · contact PI
Developmental Funds$644,639
P30 · FY2019 · CA · contact PI
Genomic Architecture of LGL Leukemia$590,474
R01 · FY2019 · CA · contact PI
University of Virginia Cancer Center Support Grant$249,724
P30 · FY2019 · CA · contact PI
Transdisciplinary Big Data Science Training at UVa$243,180
T32 · FY2019 · LM
University of Virginia Cancer Center Support Grant$146,172
P30 · FY2019 · CA · contact PI
University of Virginia Cancer Center Support Grant$91,989
P30 · FY2019 · CA · contact PI
University of Virginia Cancer Center Support Grant$60,000
P30 · FY2019 · CA · contact PI
University of Virginia Cancer Center Support Grant$50,961
P30 · FY2019 · CA · contact PI
Planning and Evaluation$49,823
P30 · FY2019 · CA · contact PI
University of Virginia Cancer Center Support Grant$29,346
P30 · FY2019 · CA · contact PI
University of Virginia Cancer Center Support Grant$2,599,349
P30 · FY2018 · CA · contact PI
Cancer Center Administration$652,210
P30 · FY2018 · CA · contact PI
Developmental Funds$643,812
P30 · FY2018 · CA · contact PI
Genomic Architecture of LGL Leukemia$609,097
R01 · FY2018 · CA · contact PI
University of Virginia Cancer Center Support Grant$247,355
P30 · FY2018 · CA · contact PI
Transdisciplinary Big Data Science Training at UVa$233,235
T32 · FY2018 · LM
University of Virginia Cancer Center Support Grant$174,039
P30 · FY2018 · CA · contact PI
University of Virginia Cancer Center Support Grant$124,862
P30 · FY2018 · CA · contact PI
University of Virginia Cancer Center Support Grant$107,460
P30 · FY2018 · CA · contact PI
Cancer Center Administration$62,065
P30 · FY2018 · CA · contact PI
Developmental Funds$61,267
P30 · FY2018 · CA · contact PI
Planning and Evaluation$49,759
P30 · FY2018 · CA · contact PI
University of Virginia Cancer Center Support Grant$48,726
P30 · FY2018 · CA · contact PI
University of Virginia Cancer Center Support Grant$35,000
P30 · FY2018 · CA · contact PI
Cancer Center Administration$10,239
P30 · FY2018 · CA · contact PI
Planning and Evaluation$10,238
P30 · FY2018 · CA · contact PI
Developmental Funds$10,238
P30 · FY2018 · CA · contact PI
Cancer Center Administration$7,345
P30 · FY2018 · CA · contact PI
Planning and Evaluation$7,345
P30 · FY2018 · CA · contact PI
Developmental Funds$7,345
P30 · FY2018 · CA · contact PI
Cancer Center Administration$6,322
P30 · FY2018 · CA · contact PI
Planning and Evaluation$6,322
P30 · FY2018 · CA · contact PI
Developmental Funds$6,322
P30 · FY2018 · CA · contact PI
Planning and Evaluation$4,736
P30 · FY2018 · CA · contact PI
Cancer Center Administration$2,867
P30 · FY2018 · CA · contact PI
Developmental Funds$2,867
P30 · FY2018 · CA · contact PI
Planning and Evaluation$2,867
P30 · FY2018 · CA · contact PI
Cancer Center Administration$2,059
P30 · FY2018 · CA · contact PI
Planning and Evaluation$2,059
P30 · FY2018 · CA · contact PI
Developmental Funds$2,059
P30 · FY2018 · CA · contact PI
University of Virginia Cancer Center Support Grant$2,574,504
P30 · FY2017 · CA · contact PI
Targeted Sphingolipid Metabolism for Treatment of AML$2,019,502
P01 · FY2017 · CA · contact PI
Cancer Center Administration$613,453
P30 · FY2017 · CA · contact PI
Genomic Architecture of LGL Leukemia$609,457
R01 · FY2017 · CA · contact PI
Developmental Funds$605,554
P30 · FY2017 · CA · contact PI
Targeting Acid Ceramidase in AML$319,896
P01 · FY2017 · CA · contact PI
Transdisciplinary Big Data Science Training at UVa$289,065
T32 · FY2017 · LM
Project-006$129,598
P30 · FY2017 · CA · contact PI
Project-006$125,000
P30 · FY2017 · CA · contact PI
University of Virginia Cancer Center Support Grant$125,000
P30 · FY2017 · CA · contact PI
University of Virginia Cancer Center Support Grant$104,087
P30 · FY2017 · CA · contact PI
Administrative Core$102,933
P01 · FY2017 · CA · contact PI
Planning and Evaluation$46,800
P30 · FY2017 · CA · contact PI
Cancer Center Support Grant$2,388,301
P30 · FY2016 · CA · contact PI
Targeted Sphingolipid Metabolism for Treatment of AML$2,019,502
P01 · FY2016 · CA · contact PI
Genomic Architecture of LGL Leukemia$630,575
R01 · FY2016 · CA · contact PI
Survival Mechanisms in Leukemic NK Cells$332,340
R01 · FY2016 · CA · contact PI
Targeting Acid Ceramidase in AML$319,896
P01 · FY2016 · CA · contact PI
Transdisciplinary Big Data Science Training at UVa$286,032
T32 · FY2016 · LM
Cancer Center Support Grant$125,000
P30 · FY2016 · CA · contact PI
Administrative Core$102,933
P01 · FY2016 · CA · contact PI
Cancer Center Support Grant$2,467,468
P30 · FY2015 · CA · contact PI
Targeted Sphingolipid Metabolism for Treatment of AML$2,077,502
P01 · FY2015 · CA · contact PI
Survival Mechanisms in Leukemic NK Cells$340,427
R01 · FY2015 · CA · contact PI
Targeting Acid Ceramidase in AML$326,341
P01 · FY2015 · CA · contact PI
Cancer Center Support Grant$150,000
P30 · FY2015 · CA · contact PI
Cancer Center Support Grant$125,000
P30 · FY2015 · CA · contact PI
Administrative Core$109,378
P01 · FY2015 · CA · contact PI
Cancer Center Support Grant$50,000
P30 · FY2015 · CA · contact PI
Characterization of the LGL Leukemia Virus (PQ 12)$35,000
R01 · FY2015 · CA · contact PI
Cancer Center Support Grant$29,167
P30 · FY2015 · CA · contact PI
Cancer Center Support Grant$2,316,653
P30 · FY2014 · CA · contact PI
Targeted Sphingolipid Metabolism for Treatment of AML$1,929,328
P01 · FY2014 · CA
Characterization of the LGL Leukemia Virus (PQ 12)$469,371
R01 · FY2014 · CA · contact PI
Targeting Acid Ceramidase in AML$317,668
P01 · FY2014 · CA · contact PI
Survival Mechanisms in Leukemic NK Cells$250,893
R01 · FY2014 · CA · contact PI
Cancer Center Support Grant$138,384
P30 · FY2014 · CA · contact PI
Administrative Core$83,005
P01 · FY2014 · CA · contact PI
Cancer Center Support Grant$75,000
P30 · FY2014 · CA · contact PI
Cancer Center Support Grant$50,000
P30 · FY2014 · CA · contact PI
Targeted Sphingolipid Metabolism for Treatment of AML$1,988,999
P01 · FY2013 · CA
Characterization of the LGL Leukemia Virus (PQ 12)$506,096
R01 · FY2013 · CA · contact PI
Targeting Acid Ceramidase in AML$327,492
P01 · FY2013 · CA · contact PI
Administrative Core$85,574
P01 · FY2013 · CA · contact PI
Survival Mechanisms in Leukemic NK Cells$63,279
R01 · FY2013 · CA · contact PI
Characterization of the LGL Leukemia Virus (PQ 12)$548,147
R01 · FY2012 · CA · contact PI
Survival Mechanisms in Leukemic NK Cells$325,911
R01 · FY2012 · CA · contact PI
Targeted Therapeutics of LGL Leukemia utilizing Ceramide Nanoliposomes$303,925
R01 · FY2012 · CA · contact PI
Survival Mechanisms in Leukemic NK Cells$329,117
R01 · FY2011 · CA · contact PI
Targeted Therapeutics of LGL Leukemia utilizing Ceramide Nanoliposomes$303,925
R01 · FY2011 · CA · contact PI
Survival Mechanisms in Leukemic NK Cells$337,029
R01 · FY2010 · CA · contact PI
Targeted Therapeutics of LGL Leukemia utilizing Ceramide Nanoliposomes$313,325
R01 · FY2010 · CA · contact PI
Survival Mechanisms in Leukemic NK Cells$336,849
R01 · FY2009 · CA · contact PI
Targeted Therapeutics of LGL Leukemia utilizing Ceramide Nanoliposomes$313,325
R01 · FY2009 · CA · contact PI
Targeted Therapeutics of LGL Leukemia utilizing Ceramide Nanoliposomes$17,452
R01 · FY2009 · CA · contact PI
Targeted Therapeutics of LGL Leukemia utilizing Ceramide Nanoliposomes$313,325
R01 · FY2008 · CA · contact PI
Survival Mechanisms in Leukemic NK Cells$315,822
R01 · FY2007 · CA · contact PI
Survival Mechanisms in Leukemic NK Cells$325,255
R01 · FY2006 · CA · contact PI
LARGE GRANULAR LYMPHOCYTE (LGL) LEUKEMIA REGISTRY PROTOCOL$3,871
M01 · FY2006 · RR · contact PI
PATHOGENESIS OF LGL LEUKEMIA$3,011
M01 · FY2006 · RR · contact PI
Survival Mechanisms in Leukemic NK Cells$333,083
R01 · FY2005 · CA
THERAPEUTIC RESPONSE IN LGL LEUKEMIA$310,628
R01 · FY2005 · CA
LARGE GRANULAR LYMPHOCYTE (LGL) LEUKEMIA REGISTRY PROTOCOL$10,878
M01 · FY2005 · RR
PATHOGENESIS OF LGL LEUKEMIA$9,858
M01 · FY2005 · RR
Survival Mechanisms in Leukemic NK Cells$333,083
R01 · FY2004 · CA
THERAPEUTIC RESPONSE IN LGL LEUKEMIA$310,628
R01 · FY2004 · CA
CLINICAL INVESTIGATIONS IN LGL LEUKEMIA$126,381
K24 · FY2004 · CA
Survival Mechanisms in Leukemic NK Cells$333,083
R01 · FY2003 · CA
THERAPEUTIC RESPONSE IN LGL LEUKEMIA$224,059
R01 · FY2003 · CA
CLINICAL INVESTIGATIONS IN LGL LEUKEMIA$126,381
K24 · FY2003 · CA
THERAPEUTIC RESPONSE IN LGL LEUKEMIA$83,850
R01 · FY2003 · CA
CLINICAL SCHOLARS IN ONCOLOGY$749,445
K12 · FY2002 · CA
THERAPEUTIC RESPONSE IN LGL LEUKEMIA$300,875
R01 · FY2002 · CA
CLINICAL INVESTIGATIONS IN LGL LEUKEMIA$126,381
K24 · FY2002 · CA
THERAPEUTIC RESPONSE IN LGL LEUKEMIA$300,875
R01 · FY2001 · CA
CLINICAL INVESTIGATIONS IN LGL LEUKEMIA$126,381
K24 · FY2001 · CA
DYSREGULATION OF APOPTOSIS IN LGL LEUKEMIA$145,000
R21 · FY2000 · CA
CLINICAL INVESTIGATIONS IN LGL LEUKEMIA$126,381
K24 · FY2000 · CA